Want to see GB:TSTL full AI Analyst Report?
TSTL Stock Chart & Stats
450.00 p
-38.00 p(-8.44%)
At close: 4:00 PM EDT
450.00 p
-38.00 p(-8.44%)
Day’s Range― - ―
52-Week Range350.00 p - 450.00 p
Previous CloseN/A
Volume139.36K
Average Volume (3M)75.90K
Market Cap
£206.39M
Enterprise Value196.48 p
Total Cash (Recent Filing)£13.29M
Total Debt (Recent Filing)£5.82M
Price to Earnings (P/E)25.8
Beta0.71
Next Earnings
Oct 19, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend Yield3.33%
Share Statistics
EPS (TTM)0.16
Shares Outstanding47,997,290
10 Day Avg. Volume83,961
30 Day Avg. Volume75,902
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)5.93
Price to Sales (P/S)4.21
P/FCF Ratio20.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.2
Revenue Forecast (FY)£56.30M
Bulls Say, Bears Say
Bulls Say
High Margins & ProfitabilityTristel's high gross margin (~81.6%) and double-digit net margin indicate durable pricing power from proprietary chemistries and consumable mix. Sustained margins support reinvestment, dividend progressivity and buffer against cyclical volume swings, underpinning long-term cash generation.
Strong Balance SheetLow leverage and a debt-free position with material cash provide strategic flexibility to fund commercial expansion, insourcing, or clinical studies without stressing liquidity. A solid equity base reduces financial risk and supports consistent dividend and investment programs.
U.S. Traction And Clinical ValidationRapidly growing U.S. procedures, distributor/OEM partnerships and guideline inclusions create a structural channel for recurring consumable sales. Clinical validation and wide probe compatibility expand addressable market and support sustained adoption and repeat revenue over coming years.
Bears Say
APAC/China WeaknessWeakness in China and APAC reflects structural exposure to region-specific healthcare financing, policy and private hospital volatility. Prolonged softness in these markets could materially dampen group growth and make global targets harder to achieve without offsetting gains elsewhere.
Free Cash Flow SlowdownA 12.7% decline in free cash flow growth, despite strong operating cash conversion, signals emerging pressure on cash available for discretionary uses. If the trend persists it could limit capacity for M&A, accelerated commercial hires or faster dividend increases.
Higher Operating Costs & Transition SpendIncreased operating spend for insourcing, commercial expansion and succession-related costs raises execution risk: benefits depend on successful hiring and commercialization. If revenue uplift lags, margin targets could be pressured despite long-term benefit potential.
Tristel News
TSTL FAQ
What was Tristel PLC’s price range in the past 12 months?
Tristel PLC lowest share price was 350.00 p and its highest was 450.00 p in the past 12 months.
What is Tristel PLC’s market cap?
Tristel PLC’s market cap is £206.39M.
When is Tristel PLC’s upcoming earnings report date?
Tristel PLC’s upcoming earnings report date is Oct 19, 2026 which is in 78 days.
How were Tristel PLC’s earnings last quarter?
Tristel PLC released its earnings results on Mar 02, 2026. The company reported 0.094 p earnings per share for the quarter, beating the consensus estimate of 0.092 p by 0.002 p.
Is Tristel PLC overvalued?
According to Wall Street analysts Tristel PLC’s price is currently Overvalued.
Does Tristel PLC pay dividends?
Tristel PLC pays a Semiannually dividend of 5.68 p which represents an annual dividend yield of 3.33%. See more information on Tristel PLC dividends here
What is Tristel PLC’s EPS estimate?
Tristel PLC’s EPS estimate is 0.09.
How many shares outstanding does Tristel PLC have?
Tristel PLC has 47,997,290 shares outstanding.
What happened to Tristel PLC’s price movement after its last earnings report?
Tristel PLC reported an EPS of 0.094 p in its last earnings report, beating expectations of 0.092 p. Following the earnings report the stock price went down -0.75%.
Which hedge fund is a major shareholder of Tristel PLC?
Currently, no hedge funds are holding shares in GB:TSTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tristel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.08%
12-Months-Change
Fundamentals
Return on Equity
3.33%
Trailing 12-Months
Asset Growth
6.03%
Trailing 12-Months
Company Description
Tristel PLC
Tristel plc is a company specializing in the creation, production, and global distribution of products designed to prevent infections, serving both its home market in the UK and international clients. Its operations are structured around three core divisions: the decontamination of medical devices within hospital environments, the disinfection of hospital-based environmental surfaces, and an additional 'Other' category. The firm offers an extensive range of disinfection solutions for medical instruments under its Tristel brand. These solutions are applied across a wide spectrum of clinical areas, including airway management, cardiology, ear, nose and throat (ENT), endoscopy, gastrointestinal physiology, laboratory applications, ophthalmology, phlebotomy, reproductive health/IVF, general surface disinfection, ultrasound, urology, and women's health, alongside other specialized products. Tristel plc was established in 1993 and has its main office situated in Snailwell, United Kingdom.
Technical Analysis
Advanced Medical Solutions
―
ConvaTec
―
CVS Group plc
―
Surgical Innovations
―
Smith & Nephew
―